ABSTRACT

Acute cervical radiculoplexus neuropathy contralateral to influenza vaccination preceded proximal and distal leg weakness, sensory loss and corresponding deficits of lumbosacral radiculoplexus neuropathy. Treatment with pulse corticosteroids followed by tapering oral corticosteroids and monthly low dose intravenous immune globulin was associated with eventual improvement.

Keywords:

Influenza, Vaccination, Microscopic Vasculitis, Epidermal Nerve Fibers, Electrodiagnostic Studies, Intravenous Immune Globulin

1. Introduction

The induction of host protective immunity is an important factor in immunization strategies to prevent epidemics in the United States (US). Protection against influenza also known as the “flu”, is a national priority. The US 2017-18 influenza season (October 1, 2017-May 19, 2018) was a high severity season with high levels of outpatient clinic and emergency department visits for influenza-like illnesses (ILI). Vaccine recommendations each year rely upon given global influenza virologic and epidemiologic surveillance, genetic characterization, antigenic characterization, and candidate vaccine viruses available for production. In 2018, the Food and Drug Administration’s Vaccines and Related Biologic Products Advisory Committee recommended the trivalent vaccine containing an A/Michigan/45/2015 A(H1N1)pdm09-like virus, an A/Singapore/INFIMH-16-0019/2016 A(H3N2)-like virus, and a B/Colorado/06/2017-like (B/Victoria lineage) [1] .

There is concern in vaccinating untreated autoimmune patients such as those with preclinical involvement and well-defined autoantibodies. A study of the immune response to exogenous stimulation associated with H1N1 vaccination in untreated Sjögren’s syndrome (SS) patients [2] showed enhanced promotion of pathogenic SS antibodies due to polyclonal B-cell activation. These findings offer one explanation for immunization-related adverse events associated with routine flu vaccination. Such events may include acute and subacute neuropathic neuromuscular disorders that conform to strict case definition [3] , effective treatment of which depends upon reaching the correct diagnosis and initiating prompt immunotherapy.

2. Patient Report

A middle-age man received a standard-dose of inactivated influenza vaccine (split virion) unadjuvanted (Fluvax®) in the upper left arm in the fall 2018. This was followed by arm pain and heaviness in the contralateral arm from the shoulder to the hand. He presented to a local emergency room where he underwent non-contrast magnetic resonance imaging (MRI) of the brain that showed scattered white matter changes. Non-contrast MRI of the brachial plexus was normal. Non-contrast MRI of the cervical and lumbar spine showed age-appropriate degenerative changes. Lumbar cerebrospinal fluid showed normal protein content without pleocytosis or evidence of infection. He received pulse intravenous corticosteroids (CS) for one week followed by a slow taper of prednisone that led to improved arm pain.

He presented one month later with insidious pain and heaviness of the proximal left thigh. Neurological examination showed right scapular winging and wasting of proximal shoulder muscles with grade 3+/5 Medical Research Council (MRC) [4] strength in the supraspinatus, infraspinatus, deltoid, biceps brachii, and serratus anterior muscles. There were light touch and temperature perception deficits along the right upper lateral arm and forearm, with grade 4/5 MRC strength in the left iliopsoas, vastus lateralis, and gluteus maximus. There was patchy anterolateral discriminative light touch and temperature sensory loss along the left thigh and calf. Tendon reflexes were hypoactive in the right arm and in both legs.

Nerve conduction studies (NCS) and electromyography (EMG) studies of the legs and right arm were consistent with cervical and lumbar radiculoplexus neuropathies. Laboratory evaluation showed a positive nuclear antibody (ANA), C1q binding assay was 4.7 ugE/ml (normal 0 to 3.9 ugE/ml), C4 was 13 mg/dL (normal 15 - 57 mg/dL), SSA was >8 AI (normal < 1 AI), and the absolute CD3+ T-cell count was 503 cells/uL (normal 656 to 1903 cell/uL), and the CD8+ T-cell subset comprised 35% (normal 11% - 33%). There were normal chemistries, complete blood count (CBC), Lyme serology, thyroid function and autoantibodies, including levels for C3, myeloperoxidase, proteinase-3, ribonucleoprotein, scleroderma-70, Smith, SSB, double-stranded deoxyribonucleic acid, total immunoglobulin (Ig) G, A and M antibodies, and anti-neutrophil cytoplasmic antibody. Intraepidermal nerve fiber (IENF) analysis of the left calf and thigh (Figure 1) showed significantly reduced mean densities. The left calf IENF density was 1.9/mm skin (range 1.2 - 2.4) and left thigh was 5.4/mm skin (range 3.4 - 7) (normal calf > 5/mm, and thigh > 8/mm) without evidence of Congo red immunofluorescence for amyloid.

He was treated with intravenous immune globulin (IVIg), 35 grams monthly for 9 months with improvement.

3. Comment

Dyck and coworkers [5] described lumbosacral radiculoplexus neuropathy (LRPN) as monophasic severe lower leg pain and weakness that commenced unilaterally, with delayed involvement of the other leg in middle-age patients with type 2 diabetics (T2D) and relatively good glycemic control; non-diabetic and diabetic (DLRPN) forms have an identical presentation [6] [7] . Electrodiagnostic studies reveal acute spontaneous activity, subacute to chronic axonal features consistent with a radiculoplexopathy (involving root, plexus and peripheral nerve), as the term LRPN implies. An etiopathogenesis that relates to ischemic microvasculitis (MV) (Figure 2) that affects arteriae nervorum measuring < 100 um in diameter, was postulated in 33 prospectively studied patients with DLRPN [5] in whom biopsy of a distal cutaneous nerve revealed neovascularization, injury neuroma, perineurial thickening, multifocal fiber loss and lymphocytic inflammation in up to one-half of biopsied nerves.

Two decades later Massie and colleagues [8] described 85 patients with T2D and cervical radiculoplexus neuropathy (CRPN), and pain and numbness overshadowed by profound weakness. In contrast to LRPN, the presentation was more acute and clinical deficits peaked in the first week. Unlike brachial plexus neuritis, which typically manifests upper trunk involvement, there was frequent involvement of the upper, middle and lower plexuses, as in our case. Electrodiagnostic studies show axonal neuropathy with evidence of paraspinal denervation. More than half of affected patients have one or more additional affected body regions including contralateral cervical, lumbosacral, and thoracic regions. Evidence of ischemic nerve injury is the predominant feature in cutaneous nerve biopsy tissues accompanied by epineurial perivasculitis (PV), defined as inflammation surrounding but not invading the vessel walls in 100% of cases, with MV so noted in two-thirds. Given the clinicopathologic similarity to the two disorders, CRPN and LRPN are in a spectrum of MV-related autoimmune disorders.

The Peripheral Nerve Society and Brighton Collaboration of Vasculitic Neuropathy [9] established respective guidelines for the classification, diagnosis, investigation, and treatment of so-called non-systemic vasculitic neuropathy (NSVN). The support of MV in the spectrum of NSVN was the finding of MV with vascular necrosis in a cutaneous sensory nerve biopsy of a patient with clinically apparent DLRPN [10] in whom postmortem examination showed PV along the sciatic and femoral nerves (Figure 3(a) and Figure (3b)), lumbar plexus and dorsal roots.

Despite its rarity, vaccination-related vasculopathy is a reportable adverse event following immunization. The condition can be permanently disabling and thus important to recognize. Hadden and colleagues [3] described guidelines for collection, analysis, and presentation of immunization safety data for reporting cases. Six such patients diagnosed with presumed NSVN, without nerve biopsy had presented clinical and electrodiagnostic findings of focal, multifocal neuropathy, and distal axonal polyneuropathy. Five had evidence of predisposing systemic conditions such as lupus, Hepatitis B virus infection, focal vasculitis of the skin or polyarteritis nodosa, only 3 of whom [11] [12] [13] received a preceding influenza immunization before onset of the neurological disorder. Treatment with IVIg therapy was associated with an improved outcome of NSVN in all those studied. The present patient was similar to other reported cases in the presence of seropositive ANA, and increased C1q binding and SSA antibody levels in association with radiculoplexus neuropathies, which have an immune etiopathogenesis causally related to MV and NSVN.

Elevated titers of SSA antibody in the serum in the present patient suggested contemporaneous SS. The full-blown disorder is characterized by xerophthalmia, xerostomia, arthralgia, myalgia and severe fatigue [14] . Lymphocytic infiltration of lacrimal salivary glands is the hallmark of the disease, which results in partial destruction of glandular parenchyma. Disease classification based on new preliminary American College of Rheumatology (ACR) criteria required a positive salivary gland biopsy or the presence of an elevated serum SSA antibody [15] . Extraglandular peripheral nervous system (PNS) involvement occurs in up to two-thirds of SS patients [16] , typically manifesting peripheral and autonomic neuropathies with a clinical presentation that depends upon the sensory neuron involved the caliber of the axon, its location and whether sensory ganglia, distal large myelinated or small unmyelinated fibers are primarily involved. Mononeuropathy multiplex, radiculoneuropathy, and sensory axonal polyneuropathies are frequent findings associated with MV [17] .

Considering that CRPN and LRPN are subtypes of NSVN, a similar treatment regimen for patients commences with CS and IVIg therapy. The benefit of CS derives from its inhibitory properties on inflammatory and immune responses. Corticosteroids are administered intravenously as methylprednisolone at a dose of 1000 mg for 3 to 5 days, followed by oral prednisone [18] followed by 1 mg/kg of oral prednisone that is slowly tapered by 5 to 10 mg every few weeks after one to two months depending on the patient’s response and severity of the disease [19] [20] . Patients with progressive symptoms early in the course of radiculoplexus neuropathy are candidates for immunotherapy with IVIg [21] . An open, uncontrolled study employing intravenous methylprednisolone in patients with clinically deteriorating LRPN, showed improvement in the Neuropathy Impairment Score commensurate with clinical improvement [22] [23] .

Disclosure

The author has nothing to disclose.

Conflicts of Interest

The author declares no conflicts of interest regarding the publication of this paper.

Cite this paper

Younger, D.S. (2019) Cervical and Lumbosacral Radiculoplexus Neuropathy Following Influenza Vaccination. World Journal of Neuroscience, 9, 255-261. https://doi.org/10.4236/wjns.2019.94019

References